Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.54 |
| ▸ | KDR | P35968 | 12/20 | 0.46 |
| ▸ | AXL | P30530 | 11/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12004026 | 0.89 | MET (0.53) | METKDRAXLFLT4TEK | |
| SCHEMBL29812085 | 0.84 | TRPA1 (0.53) | METKDRAXLTEK | |
| SCHEMBL199658 | 0.84 | TRPA1 (0.53) | METKDRAXLTEK | |
| Hydrochloric Acid SCHEMBL14967852 | 0.83 | TRPA1 (0.52) | METKDRAXLTEK | |
| SCHEMBL12003753 | 0.83 | MET (0.53) | METKDRAXLFLT4TEK | |
| SCHEMBL12004568 | 0.81 | MET (0.53) | METKDRAXLFLT4TEK | |
| SCHEMBL374195 | 0.79 | CYP3A4 (0.45) | METKDRAXLFLT4TEK | |
| SCHEMBL15889727 | 0.77 | AXL (0.48) | METKDRAXL | |
| SCHEMBL12003999 | 0.77 | MET (0.51) | METKDRAXLFLT4TEK | |
| SCHEMBL29812263 | 0.75 | AXL (0.52) | METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421038-A1 | NAPHTHYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Nanjing Natinefy Pharmatech Co., Ltd. (CN) | 2019-01-02 | — | — | EP | disclosed |
| WO-2018064852-A1 | NAPHTHYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 南京纳丁菲医药科技有限公司 | 2018-04-12 | — | — | WO | disclosed |
| US-20180099962-A1 | NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-12 | — | — | US | disclosed |
| US-20180099962-A1 | NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-12 | — | — | US | disclosed |
| US-9938274-B1 | Naphthyridine compounds, medical combinations and use thereof | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938274-B1 | Naphthyridine compounds, medical combinations and use thereof | NANJING NATINEFY PHARMATECH CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099962-A1 | NAPHTHYRIDINE COMPOUNDS, MEDICAL COMBINATIONS AND USE THEREOF | NPM1, NEK4, NME1 | MET 837/4885KDR 2288/4885AXL 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.